RYTVEL Biotech

RYTVEL Biotech is focusing on developing drugs to turn off inflammation using small peptides exhibiting allosteric properties targeting major pro-inflammatory receptors like interleukin 1R.

The lead product, Rytvela (a selective antagonist of the IL-1 receptor) has strong anti-inflammatory property and is currently developed for the treatment of the cause and ensuing serious consequences of preterm birth.

MISSION

RYTVEL’s mission is to prevent and cure inflammation by developing first-in-class therapeutic solutions.

VISION

RYTVEL Biotech will be the first company exploring a new paradigm therapy to develop Rytvela, an effective drug to end preterm birth to the benefit of women and newborns.